美银证券:重申云顶新耀-B“中性”评级 目标价上调至55.8港元

智通财经网
28 Mar

智通财经APP获悉,美银证券发布研报称,随着销售逐步提升、2024年Nefecon纳入国家医保药品目录以及管线产品的稳定进展,对云顶新耀-B(01952)在2025至2027年的收入增长更具信心。同时,由于规模效应,将2025至27年各年毛利率预测分别上调0.3个百分点、0.5个百分点和0.5个百分点。提高销售、一般和管理费用的预测,但降低了研发费用预测,这是由于业务扩张以及研发效率提升所致。因此...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10